http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160099263-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b4be2300a741a69aa1b8bb47a88899f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 |
| filingDate | 2015-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_175ed71672bb64357aa6dc4e72642116 |
| publicationDate | 2016-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20160099263-A |
| titleOfInvention | Pharmaceutical composition containing resveratrol for treating type I Gaucher Disease |
| abstract | Resveratrol is naturally occurring polyphenol having various properties, such as anti-inflammatory, anti-oxidant and neuroprotection effects. According to the present invention, the effect of resveratrol upon treatment of Type 1 fibroblasts derived from a patient suffering from Gaucher disease is evaluated. The effect of resveratrol upon cell viability is evaluated by MTT analysis. To determine the effect of resveratrol upon the cells of a patient suffering from Gaucher disease, Western immunoblot is carried out to evaluate variations in expression of AIF, Bax, cleaved caspase-3, ACAT1, E3BP and CS. In addition, thin film chromatography is carried out to determine the intracellular glucosylceramide (glucocerebroside) concentration in the cells treated with resveratrol. As a result, the cells treated with resveratrol shows a significant increase in viability as compared to the control cells. After the treatment with resveratrol, the expression levels of cell apoptosis factors, AIF, Bax and cleaved caspase-3 are increased in a dose-dependent manner. The TLC results demonstrate a significant decrease in glucosylceramide in the cells of a patient suffering from Gaucher disease, treated with resveratrol. Such results demonstrate that resveratrol decreases cell apoptosis, reduces glucosylceramide concentration, and thus can be used as a treatment agent. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019088408-A1 |
| priorityDate | 2015-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 142.